Oyagen, Inc.

oyagen is a biotechnology company formed on september 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit rna editing and dna editing enzymes. oyagen holds exclusive rights to important technologies originating from the university of rochester medical center (urmc), the thomas jefferson university (tju), and oregon health science center. over the past decade, a series of research advances have identified two families of related enzymes known as editing enzymes. these enzymes are endogenous cellular proteins, which chemically alter rna or dna molecules and thereby change the genetic code. oyagen believes that there is a significant opportunity to “harness the editing process” to create therapies for a number of disease states. oyagen’s initial therapeutic focus is a novel approach to the treatment of human immunodeficiency virus (hiv). this initial focus on hiv is driven by a series of ground breaking discoveries t